Targovax AS today announces they will receive 9 million NOK in grant from Innovation Norway to initiate a phase II/III clinical study of TG01 in operable pancreatic cancer. TG01 is a cancer vaccine which activates the body’s own immune system to recognize and kill cancer cells which have a mutated RAS-molecule.